Clarus Therapeutics Overview
- Year Founded
-
2004
- Status
-
Out of Business
- Employees
-
32
- Latest Deal Type
-
Out of Business
Clarus Therapeutics General Information
Description
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Contact Information
Website
www.clarustherapeutics.comCorporate Office
- 555 Skokie Boulevard
- Suite 340
- Northbrook, IL 60062
- United States
Corporate Office
- 555 Skokie Boulevard
- Suite 340
- Northbrook, IL 60062
- United States
Clarus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Out of Business | 03-May-2024 | Completed | Out of Business | |||
| 15. Bankruptcy: Admin/Reorg | 05-Sep-2022 | Completed | Bankruptcy: Admin/Reorg | |||
| 14. 2PO | 27-Apr-2022 | Completed | Generating Revenue | |||
| 13. PIPE | 07-Dec-2021 | Completed | Generating Revenue | |||
| 12. Reverse Merger | 09-Sep-2021 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series D) | 26-Apr-2021 | Completed | Generating Revenue | |||
| 10. Debt - General | 16-Mar-2020 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series D) | 31-Jul-2015 | Completed | Clinical Trials - Phase 3 | |||
| 8. IPO | 15-Apr-2015 | $86.2M | Cancelled | Clinical Trials - Phase 3 | ||
| 7. Later Stage VC (Series D) | 15-Feb-2013 | $21M | $64.1M | Completed | Clinical Trials - Phase 3 |
Clarus Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 5,066,637 | $0.001000 | $1 | $1 | 1x | $1.82 | 6.13% | |
| Series A | 2,500,000 | $0.001000 | $1 | $1 | 1x | $1.82 | 3.02% |
Clarus Therapeutics Comparisons
Industry
Financing
Details
Clarus Therapeutics Competitors (52)
One of Clarus Therapeutics’s 52 competitors is Gyre Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gyre Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Marinus Pharmaceuticals | Private Equity-Backed | Radnor, PA | ||||
| Abeona Therapeutics | Corporation | Cleveland, OH | ||||
| Roivant Sciences | Formerly PE-Backed | New York, NY | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Clarus Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Clarus Therapeutics Patents
Clarus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020210501-A1 | Oral pharmaceutical products and methods of use combining testosterone esters with anti-hypertensive agents | Inactive | 12-Apr-2019 | ||
| WO-2020132163-A1 | Methods of treating testosterone deficiency | Inactive | 20-Dec-2018 | ||
| WO-2018213772-A1 | Methods of treating testosterone deficiency | Inactive | 18-May-2017 | ||
| JP-2016028087-A | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising the same | Active | 17-Sep-2015 | ||
| JP-2015134803-A | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising the same | Active | 10-Mar-2015 |
Clarus Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Clarus Therapeutics Acquisitions (1)
Clarus Therapeutics’s most recent deal was a Merger/Acquisition with Blue Water Acquisition. The deal was made on 09-Sep-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Blue Water Acquisition | 09-Sep-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Clarus Therapeutics FAQs
-
When was Clarus Therapeutics founded?
Clarus Therapeutics was founded in 2004.
-
Where is Clarus Therapeutics headquartered?
Clarus Therapeutics is headquartered in Northbrook, IL.
-
What is the size of Clarus Therapeutics?
Clarus Therapeutics has 32 total employees.
-
What industry is Clarus Therapeutics in?
Clarus Therapeutics’s primary industry is Pharmaceuticals.
-
Is Clarus Therapeutics a private or public company?
Clarus Therapeutics is a Private company.
-
What is Clarus Therapeutics’s current revenue?
The current revenue for Clarus Therapeutics is .
-
How much funding has Clarus Therapeutics raised over time?
Clarus Therapeutics has raised $241M.
-
Who are Clarus Therapeutics’s competitors?
Gyre Therapeutics, Marinus Pharmaceuticals, Abeona Therapeutics, Roivant Sciences, and Alnylam Pharmaceuticals are some of the 52 competitors of Clarus Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
